question_id stringlengths 8 8 | question stringlengths 96 467 |
|---|---|
prwe-001 | Is there any evidence showing whether abatacept or adalimumab carries a higher risk of hospitalization for infection in patients with rheumatoid arthritis. Thank you. |
prwe-002 | 2nd try - in rheumatoid arthritis patients with chronic obstructive pulmonary disease (COPD), which is the better pick to avoid pneumonia admission, abatacept versus adalimumab? |
prwe-003 | In all patients with hormone receptor positive, HER2 negative metastatic breast cancer, does abemaciclib vs palbociclib cause more neutropenia, or is there no real difference between them? |
prwe-004 | In older women with hormone receptor positive, HER2 negative metastatic breast cancer, which carries the higher rate of emergency department visits from 3 to 12 months, abemaciclib versus palbociclib? |
prwe-005 | 2nd try - abemaciclib vs palbociclib, less diarrhea in the first year, diabetics with breast cancer. |
prwe-006 | Use the 3-12 month follow-up interval. AF with prior CHF: how do rate and pharmacologic rhythm control compare for HF hospitalization? |
prwe-007 | What's the rate of inpatient hospitalization with alectinib vs crizotinib in ALK-positive non-small cell lung cancer? Same for emergency department visits? |
prwe-008 | Use the 3-12 month follow-up interval. Can tamsulosin slow lower urinary tract symptom progression more than doxazosin, terazosin, or alfuzosin in BPH patients with a BMI of 36? |
prwe-009 | Use the 3-12 month follow-up interval. RLS with eGFR under 60: how does orthostatic dizziness compare for an alpha-2-delta ligand versus ropinirole? |
prwe-010 | Among the overall population for Ankylosing Spondylitis Biologic DMARD comparison: TNF Inhibitors versus IL17 Inhibitors, how does AS related hospitalization length of stay (LOS) compare during the first 3 months? |
prwe-011 | What is the difference in diarrhea across the Ankylosing spondylitis first-line therapy: TNF Inhibitors versus Non TNF Biologics options during the first 3 months? |
prwe-012 | P: overall population for Anti-VEGF versus Intravitreal Dexamethasone Implant in Retinal Vein Occlusion; C: study options; O: cataract progression; T: during the first 3 months. |
prwe-013 | I am choosing among the options for Apixaban versus Rivaroxaban versus Dabigatran in Atrial Fibrillation. How does ischemic stroke compare during the next 3 months? |
prwe-014 | Does composite MACE hospitalization differ during months 0-3 for Apremilast versus Deucravacitinib in Plaque Psoriasis? |
prwe-015 | Is there published evidence comparing aspirin versus clopidogrel as maintenance single antiplatelet therapy after PCI, with respect to MACE in the overall patient population? Thank you. |
prwe-016 | (Rephrased) In my patients with depression taking atogepant versus propranolol for episodic migraine prevention, does atogepant reduce emergency department visits at a year? |
prwe-017 | is there evidence on discontinuation rates with qulipta vs inderal for episodic migraine prevention in the first year? thanks |
prwe-018 | whats the likelihood atogepant versus topiramate lowers ED visits for migraine in patients with depression at 3 to 12 months? |
prwe-019 | In women with obesity started on preventive therapy for episodic migraine, is the discontinuation rate higher with atogepant vs Topiramate (rates for each drug would help). |
prwe-020 | Among the overall population for Atopic Dermatitis initial therapy: Triamcinolone Topical versus Crisaborole Topical, how does lichenification progression compare during the first 3 months? |
prwe-021 | Question frame: Atrial Fibrillation on Rate Control add-on: Antiarrhythmics versus Catheter Ablation; outcome=atrial fibrillation recurrence; stratum=overall; interval=0-3 months. |
prwe-022 | Use the 3-12 month follow-up interval. 58-year-old starting dialysis access: fistula or graft, access-site infections? |
prwe-023 | Is vemous thromboembolism meaningfully more common with baricitinib vs tofacitinib in rheumatoid arthritis patients over 65, 3 to 12 months, see attached? |
prwe-024 | In RA patients with cardiovascular disease, any data on MACE with baricitinib compared to tofacitinib over the first year |
prwe-025 | In women with RA, does baricitinib lead to more hospital admissions for infection compared to tofacitinib, or are the two agents similar in this respect? |
prwe-026 | Obese psoriasis patients: is there evidence bimekizumab compared to secukinumab gives less thrush over the first year? |
prwe-027 | Use the 3-12 month follow-up interval. Osteoporosis with eGFR under 60: how does atypical femur-fracture risk compare for bisphosphonates versus denosumab? |
prwe-028 | Overall population for BPH Finasteride versus Dutasteride 5-ARI add-on to Alpha-Blocker: compare catheterization procedure count during months 0-3. |
prwe-029 | Clinical context: Buprenorphine Naloxone versus Methadone versus Naltrexone for Opioid Use Disorder; Population: overall cohort; Interval: months 0-3; Outcome: inpatient due to opioid use disorder length of stay. |
prwe-030 | Overall cohort; Cabergoline versus Bromocriptine in Hyperprolactinemia Prolactinoma; assess pituitary surgery count over the first 3 months. |
prwe-031 | For the overall population in Cancer Associated Thrombosis LMWH versus DOAC, how does blood loss anemia compare over the first 3 months? |
prwe-032 | What's the rate of psychiatric hospitalization in each arm over the first year among patients with obesity (BMI >30) started and kept on cariprazine compared to aripiprazole for BD-I maintenance? |
prwe-033 | (Rephrased) What's the evidence that vraylar lowers the risk of hyperglycemia compared to abilify across all patients on maintenance treatment for BD-I in the months after starting either one? |
prwe-034 | For a patient who matches CBT-I versus Pharmacotherapy in Insomnia, I need the comparison for fall and fracture over the first 3 months. What does the evidence show? |
prwe-035 | Among all patients being treated for MSSA bacteremia, how much does Ancef reduce the likelihood of a hospital admission for acute kidney injury when compared to nafcillin as antistaphylococcal therapy? |
prwe-036 | In MSSA bacteremia patients with renal impairment (eGFR under 60), which has the longer inpatient length of stay, cefazolin vs nafcillin? |
prwe-037 | Is cenobamate or lacosamide the better second choice in focal epilepsy after first-line failure if the goal is fewer emergency department visits for patients overall? |
prwe-038 | Any data on cenobamate vs lacosamide for focal epilepsy with depression after first-line failure, which better avoids psychiatric admission per the attached case? |
prwe-039 | I am reviewing Cerebrovascular Disease With Atherosclerosis Antiplatelet Therapy Clopidogrel versus Ticagrelor for a patient. What is the difference in hemorrhagic stroke count during months 0-3? |
prwe-040 | Overall cohort; Cerebrovascular Disease With Atherosclerosis Antiplatelet Therapy Clopidogrel versus Ticagrelor; assess inpatient due to ischemic stroke length of stay over the first 3 months. |
prwe-041 | During the first 3 months, how does diarrhea compare for Chronic Hepatitis B Tenofovir Disoproxil versus Tenofovir Alafenamide? |
prwe-042 | What is the difference in diarrhea across the Chronic Hepatitis B Tenofovir versus Entecavir options during the first 3 months? |
prwe-043 | Does sinus surgery count differ during months 0-3 for Chronic sinusitis dupilumab versus Omalizumab? |
prwe-044 | I am reviewing Chronic Spontaneous Urticaria Omalizumab versus High-Dose Antihistamine for a patient. What is the difference in urticaria relapse count during months 0-3? |
prwe-045 | Question frame: Chronic Urticaria initial therapy: Dupilumab versus Omalizumab; outcome=urticaria relapse flare count; stratum=overall; interval=0-3 months. |
prwe-046 | Across all dialysis patients treated for secondary hyperparathyroidism of chronic kidney disease, is MACE more frequent with cinacalcet vs parathyroidectomy, and if so, by what magnitude of absolute risk? |
prwe-047 | In CKD patients on dialysis with secondary hyperparathyroidism and heart failure, higher inpatient admission rate with cinacalcet or parathyroidectomy at a year? |
prwe-048 | Clinical context: CKD Anemia Epoetin Alfa versus Darbepoetin Alfa ESA Head to Head; Population: overall cohort; Interval: months 0-3; Outcome: deep vein thrombosis count. |
prwe-049 | Use the 3-12 month follow-up interval. COPD with prior CHF: how does severe-exacerbation hospital stay compare for LAMA, LABA, and LAMA-LABA? |
prwe-050 | During the first 3 months, how does emergency department (ED) visit COPD utilization count compare for COPD Pulmonary Rehabilitation versus Usual Care? |
prwe-051 | What is the rate of hospitalization for chronic obstructive pulmonary disease exacerbation in patients taking roflumilast or azithromycin for prophylaxis? |
prwe-052 | Any data on whether Daliresp lowers diarrhea compared to Zithromax for chronic obstructive pulmonary disease exacerbation prophylaxis in patients with heart failure, and also the absolute numbers in each group? |
prwe-053 | What is the difference in respiratory hospitalization length of stay (LOS) across the Pulmonary sarcoidosis: corticosteroid versus methotrexate options during the first 3 months? |
prwe-054 | In all patients admitted with skin and soft tissue infection, does Dalvance or vancomycin give longer inpatient length of stay over the following year? |
prwe-055 | How much more likely is hospitalization for acute kidney injury with dalbavancin compared to vancomycin in patients with an eGFR under sixty treated for skin and soft tissue infection? |
prwe-056 | (Rephrased) In all patients with proteinuric CKD, which agent is the better choice for avoiding hospitalization for acute kidney injury over the first year, dapagliflozin or ramipril. |
prwe-057 | What is the reported rate of hyperkalemia in patients with diabetes and proteinuric Chronic Kidney Disease treated with an SGLT2 inhibitor versus Ramipril? |
prwe-058 | Do SGLT2 inhibitors vs DPP-4 inhibitors cause more hospitalization for acute kidney injury in diabetics on metformin with eGFR under 60, same question for hyperkalemia. |
prwe-059 | What's the evidence on hypoglycemia with dapagliflozin vs sitagliptin in diabetics on metformin? thanks |
prwe-060 | If I am choosing between an SGLT2 inhibitor or a DPP-4 inhibitor for a woman with diabetes already taking metformin, which one lowers her risk of urinary tract infection? Thanks. |
prwe-061 | (Rehprased) Diabetics over 65 requiring basal insulin, insulin degludec vs insulin glargine U300. Does one cause more episodes of glucose <70 than the other? |
prwe-062 | In diabetics with an eGFR under 60 requiring basal insulin, does insulin degludec versus insulin glargine U300 cause more emergency department visis? |
prwe-063 | Is insulin degludec associated with a lower rate of uncontrolled hyperglycemia compared to insulin glargine U300 in type 2 diabetics with obesity requiring basal insulin? Uncontrolled hyperglycemia here means an HbA1c lab result above 9, and the incidence in each arm would be helpful. |
prwe-064 | Use the 3-12 month follow-up interval. What dementia admission length-of-stay difference separates donepezil-memantine, donepezil, memantine, or rivastigmine, with diarrhea? |
prwe-065 | Per attached, do emergency department visits differ for a dual orexin receptor antagonist vs zolpidem in chronic insomnia, per arm? |
prwe-066 | P: overall population for DPP-4 Inhibitors versus Sulfonylureas as Second-Line Therapy in Type 2 Diabetes; C: study options; O: blood glucose > 200 (elevated diabetes); T: during the first 3 months. |
prwe-067 | Question frame: Drug Resistant Epilepsy Surgery versus Continued AED Therapy; outcome=sudden unexpected death epilepsy count; stratum=overall; interval=0-3 months. |
prwe-068 | T: months 0-3; P: overall cohort for Osteoporosis treatment with Romosozumab versus Teriparatide; O: hip fracture; C: treatment groups. |
prwe-069 | For patients eligible for Osteoporosis treatment with Romosozumab versus Teriparatide, what is the difference in vertebral fracture over the first 3 months? |
prwe-070 | What is treatment discontinuation with elagolix or leuprolide for endometriosis at 6 months, each drug separately, and also the reasons for stopping? |
prwe-071 | What's the better choice for keeping emergency department visits down in women with obesity treated for endometriosis-associated pain, elagolix versus leuprolide? |
prwe-072 | In all patients with type 2 diabetes and cardiovascular disease, how much more diabetic ketoacidosis occurs with an SGLT2 inhibitor vs a DPP-4 inhibitor? |
prwe-073 | Clinical context: Endometriosis initial therapy: Combined Oral Contraceptives versus GnRH Agonists versus GnRH Antagonists; Population: overall cohort; Interval: months 0-3; Outcome: laparoscopic excision endometriosis. |
prwe-074 | During the first 3 months, how does aortic aneurysm rupture compare for Endovascular Repair EVAR versus Open Surgical Repair for Abdominal Aortic Aneurysm? |
prwe-075 | T: months 0-3; P: overall cohort for Endovascular Repair EVAR versus Open Surgical Repair for Abdominal Aortic Aneurysm; O: graft failure thrombosis; C: treatment groups. |
prwe-076 | Is there comparative evidence on bradycardia in patients treated with propranolol vs primidone for ET, and does either agent carry a clearly greater risk? |
prwe-077 | 2nd try - hyperkalemia risk higher with finerenone vs SGLT2 inhibitor in chronic kkidney disease with type 2 diabetes, 3 to 12 months? |
prwe-078 | In type 2 diabetes with CKD and heart failure, does finerenone vs SGLT2 inhibitor reduce heart failure hospitalization over the following year |
prwe-079 | Any evidence on finerenone vs an SGLT2 inhibitor in patients over 75 with CKD and type 2 diabetes for acute kidney injury (admissions) over the following year |
prwe-080 | For Finerenone versus SGLT2 Inhibitor for Disease Modification in Diabetic CKD, what is the difference in chronic kidney disease (CKD)-related hospitalization length of stay during the first 3 months? |
prwe-081 | T: months 0-3; P: overall cohort for Focal Seizures initial therapy: Levetiracetam versus Lamotrigine; O: seizure recurrence count; C: treatment groups. |
prwe-082 | What is more likely to lead to emergency department visits for migraine in chronic migraine prevention, Ajovy versus Topamax? |
prwe-083 | Which has fewer discontinuations in women with chronic migraine, fremanezumab versus topiramate? |
prwe-084 | For an eligible patient in Peripheral neuropathy: gabapentinoids versus amitriptyline, duloxetine, or opioids, what happens to fall related fracture neuropathy count over the first 3 months? |
prwe-085 | During the first 3 months, how does acute myocardial infarction (MI) compare for Gout Prophylaxis initial therapy: Allopurinol versus Febuxostat? |
prwe-086 | Clinical context: Gout Prophylaxis initial therapy: Allopurinol versus Febuxostat; Population: overall cohort; Interval: months 0-3; Outcome: stroke. |
prwe-087 | Does disseminated zoster count differ during months 0-3 for Herpes Zoster initial therapy: Acyclovir versus Valacyclovir? |
prwe-088 | Is there evidence on whether Veltassa or Lokelma results in fewer episodes of recurrent hyperkalemia in patients with chronic hyperkalemia on RAAS inhibitors? |
prwe-089 | What's the emergency department visits for each arm, patiromer versus sodium zirconium cyclosilicate, in CKD patients (eGFR under 60) with chronic hyperkalemia on RAAS inhibitors? |
prwe-090 | In all patients with moderate to severe Crohn's disease, does Stelara or Entyvio do more to reduce inpatient hospitalization, or is neither clearly better at keeping these patients out of the hospital? |
prwe-091 | in patients with anemia and moderate to severe Crohn's, Stelara vs Entyvio, which one ends up with more ED visits? |
prwe-092 | Within the first 3 months, is blood glucose > 200 (elevated diabetes) different across the groups in Insulin versus Metformin in Gestational Diabetes? |
prwe-093 | P: overall population for Iron Deficiency Anemia Oral Iron versus Intravenous Iron; C: study options; O: persistent anemia count; T: during the first 3 months. |
prwe-094 | For Ischemic Stroke Secondary Prevention Clopidogrel versus Aspirin, what is the difference in recurrent ischemic stroke length of stay during the first 3 months? |
prwe-095 | hemorrhagic stroke, first 3 mo: compare groups in Ischemic Stroke Secondary Prevention Clopidogrel versus Aspirin. |
prwe-096 | istradefylline vs safinamide in adults over 65 with parkinson's disease and motor fluctuations, what is the rate of hip fracture in each arm and is the incidence meaningfully higher with one agent in this older group? |
prwe-097 | Any comparative data on intracranial hemorrhage with lecanemab vs donanemab in all patients with early symptomatic Alzheimer's disease? |
prwe-098 | Is there any data on whether lecanemab versus donanemab leads to more emergency department visits in adults over 75 who are being treated for early symptomatic AD? |
prwe-099 | Does combination levothyroxine and liothyronine versus levothyroxine alone increase atrial fibrillation in persistent hypothyroid symptoms, and by how much? Thanks. |
prwe-100 | My patient fits the overall population for Levodopa versus Pramipexole versus Rasagiline in Parkinson Disease Initial Therapy. What do the groups show for PD-related hospitalization length of stay (LOS) during the first 3 months? |
Precision Evidence Bench
Precision Evidence Bench is a Precision Medicine Benchmark from Atropos Health, the world's largest creator of real-world evidence (RWE) for clinical decision support. It evaluates how well large language models (LLMs) answer clinical questions that are grounded in patient context and inclusive of patient history: not "which treatment is better in general", but "which treatment is better for this patient", with a specific comorbidity, age, prior therapy or other characteristic that changes the answer.
A system under test is asked to do one thing: given a question a physician might actually type about a specific patient, find the evidence that answers it for that patient and report that evidence faithfully, including when no such evidence exists.
We are releasing it openly so that anyone building or evaluating clinical question-answering systems, whether grounded in the literature, in real-world data, or in web search, can test against the same questions and grade with the same rubric. Results from different systems are comparable when they use both.
What is in the benchmark
209 questions, each written against a specific comparison of two or more treatments, a patient population defined by clinical context and history, an outcome, and a follow-up window, then rendered in a clinical voice. Many questions name the patient characteristic that matters, such as a comorbidity, an age group, a lab threshold or a prior treatment, and a correct answer must match that patient rather than the general population. Some questions carry a follow-up-window instruction (0–3 or 3–12 months). Some target comparisons for which no real-world study exists, so the benchmark also measures how a system behaves when the evidence base is empty. All questions are synthetic and contain no patient data.
A five-item grading rubric (rubric.json) that scores an answer against the
question and the answer's own citations, so no reference answer is needed to
grade:
| Rubric item | Asks whether |
|---|---|
faithful_to_sources |
the answer does not misrepresent what its cited sources show, judged as a clinician deciding whether to act on it, not as word-for-word traceability |
single_source_full_pico_match |
one cited source matches the question's full population, intervention, comparator and outcome, including any required patient subgroup |
single_source_pic_match |
one cited source matches population, intervention and comparator |
single_source_pio_match |
one cited source matches population, intervention and outcome |
single_source_pco_match |
one cited source matches population, comparator and outcome |
Each item carries the exact prompt text we give to an LLM juror. Internally we use a panel of three LLM jurors from different providers and take the fraction that agree on each item; any grader that answers the five items works.
How to use it
- Pose each
questionto your system exactly as written, and have it return an answer with citations. - Grade each answer on the five rubric items, using
rubric.jsonas the grader's instructions. - Report results per item, or collapse them into a single rating. Our convention, with an item counting as true when a majority of jurors agree: full PICO match and faithful is the top rating; faithful with two, one or no partial matches step down from there; not faithful is the bottom rating regardless of matching.
Files
| File | Contents |
|---|---|
questions.csv |
question_id (prwe-001 … prwe-209) and question |
rubric.json |
The five rubric items with their grader prompts |
MANIFEST.json |
Row count, SHA-256 per file, and the source commit |
This release contains the questions and rubric only. Reference labels and our own model results are not included in this version.
Reporting results and contributing
If you evaluate a system on this benchmark, we would like to hear about it. Open a discussion on this dataset's page with the system evaluated, the grader used, and per-item scores. Corrections to individual questions are welcome the same way.
License and citation
Released under the Creative Commons Attribution-ShareAlike 4.0 International license
(cc-by-sa-4.0): use, share and adapt it freely, with attribution to Atropos
Health, and release derivatives under the same license.
Please cite the dataset as Atropos Health, Precision Evidence Bench: a Precision Medicine Benchmark for evidence-based clinical question answering (2026), https://huggingface.co/datasets/atroposhealth/precision-evidence-bench.
Provenance
Built by scripts/build_hf_release.py in Atropos Health's prwe_bench
repository; MANIFEST.json records the source commit and file hashes. Built
2026-09-17.
- Downloads last month
- 97